Opdivo vs Imbruvica
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Opdivo | US Imbruvica | |
|---|---|---|
| Generic name | nivolumab | ibrutinib |
| Drug class | PD-1 Inhibitor (Immunotherapy) | BTK Inhibitor |
| Treats | Multiple cancers | Chronic lymphocytic leukemia and other blood cancers |
| Category | Oncology | Oncology |
| Manufacturer | Bristol-Myers Squibb | AbbVie/Janssen |
| Year approved | 2014 | 2013 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $150M | — |
| Common side effects | Immune-related side effects, Fatigue, Rash, Diarrhea | Bleeding and bruising, Irregular heartbeat (atrial fibrillation), High blood pressure, Infections |
Frequently asked questions
Is Opdivo or Imbruvica better?
Neither is universally "better." Opdivo (nivolumab) and Imbruvica (ibrutinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Opdivo and Imbruvica?
Opdivo is a PD-1 Inhibitor (Immunotherapy) made by Bristol-Myers Squibb, while Imbruvica is a BTK Inhibitor made by AbbVie/Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Opdivo has the larger estimated TV advertising budget of the two.